Clinical trials: c-MET
Head and Neck Cancer, Penile Cancer
INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue
In this study we evaluate the feasibility of intraoperative visualization of penile and tongue tumours using the fluorescent tracer EMI-137.
- Trial name
- INFLUENCE (NCT04574427)
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- The Netherlands Cancer Institute
Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC V7
Lung-MAP S1400K: c-MET Positive
S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer…
- Trial name
- NCT03574753
- Testing
- ABBV-399
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- SWOG Cancer Research Network
Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors.
- Conditions
- Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma
- Trial name
- PROFILE 1001 (NCT00585195)
- Testing
- PF-02341066, Rifampin, Itraconazole
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 596 people
- Sponsor
- Pfizer
Solid Cancers
A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase I, open label, dose-escalation study of MetMAb administered by intravenous (IV) infusion in patients with advanced solid malignancies that are refractory to or for which there is no standard of care.
- Trial name
- NCT01068977
- Testing
- bevacizumab, MetMAb
- Volunteers
- 44 people
- Sponsor
- Genentech, Inc.
c-MET Positive Gastric Cancer
A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
This is a pilot study of crizotinib in patients with c-MET positive gastric adenocarcinoma.
- Trial name
- NCT02435108
- Testing
- crizotinib
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Samsung Medical Center
Cancer
A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.
This a first-in-human study of an antibody blocking the function of the oncogene c-met in patients with cancer.
- Trial name
- NCT02055066
- Testing
- ARGX-111
- Where
- 2 sites in Belgium
- Volunteers
- 24 people
- Sponsor
- argenx
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
This is a Phase 1/2a open-label multicenter study to evaluate the safety, efficacy, and pharmacokinetics of CKD-703 in Advanced c-Met Expressing Solid Tumors, and in MET-Amplified and c-Met Overexpressing Non-Small Cell Lung…
- Trial name
- NCT07439094
- Testing
- CKD-703
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Advanced Malignancies
Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies
In this study, MGCD265, a new anticancer drug under investigation, is given daily on a 7 days on / 7 days off schedule to patients with advanced malignancies to study its safety profile.
- Trial name
- NCT00679133
- Testing
- MGCD265
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Mirati Therapeutics Inc.
Non-Small Cell Lung Cancer
An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC) and its administration has…
- Trial name
- NCT02708667
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide and in China. The purpose of this study is to assess adverse events and change in disease activity of intravenously (IV) infused telisotuzumab…
- Trial name
- NCT06614192
- Testing
- Telisotuzumab Adizutecan
- Where
- 51 sites in United States, Australia and 5 more
- Volunteers
- 74 people
- Sponsor
- AbbVie
Colorectal Cancer (CRC)
Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer
The goal of this clinical trial is to learn if adding savolitinib to cetuximab plus FOLFOX chemotherapy works as a first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer, and to evaluate its…
- Trial name
- NCT07683403
- Testing
- Savolitinib plus cetuximab and FOLFOX chemotherapy, Cetuximab and FOLFOX chemotherapy
- Where
- 5 sites in China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, efficacy, PK profile and immunogenicity of HS-20117 in combination with other…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- HS-20117 (NCT06621563)
- Testing
- HS-20117 combined HS-20093, HS-20117 combined Platinum-containing chemotherapy, HS-20117 combined HS-20093 and 5-FU
- Where
- China
- Volunteers
- 780 people
- Sponsor
- Hansoh BioMedical R&D Company
Unspecified Adult Solid Tumor, Protocol Specific
TR1801-ADC in Patients With Tumors That Express c-Met
First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of TR1801-ADC in patients with select solid tumors that express c-Met.
- Trial name
- NCT03859752
- Testing
- TR1801-ADC
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Open Innovation Partners, Inc.
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Non Squamous, Non-small-cell Lung Cancer
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
This study is to determine if the combination regimen of tivantinib with erlotinib will improve overall survival relative to erlotinib alone in subjects with locally advanced or metastatic non-squamous, non-small cell lung cancer…
- Trial name
- NCT01244191
- Testing
- Tivantinib, Erlotinib
- Where
- 304 sites in United States, Argentina and 21 more
- Volunteers
- 1,048 people
- Sponsor
- Daiichi Sankyo
Solid Tumors, Advanced Cancer
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
To assess: efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion…
- Conditions
- Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer
- Trial name
- SPARTA (NCT03175224)
- Testing
- APL-101 Oral Capsules
- Where
- 35 sites in United States, Australia and 9 more
- Volunteers
- 497 people
- Sponsor
- Apollomics Inc.
Advanced Hepatocellular Carcinoma With c-MET Dysregulation
Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.
This study is to find out if INC280 is safe and has beneficial effects in patients with advanced hepatocellular carcinoma known to have dysregulation of c-MET pathway.
- Trial name
- NCT01737827
- Testing
- INC280
- Where
- 8 sites in China, Hong Kong and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Solid Tumor, Adult
A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
To investigate safety, tolerability and pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours that are not eligible for conventional or intensive treatment.
- Trial name
- NCT02977364
- Testing
- HS-10241
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Carcinoma, Non-Small Cell Lung, Adenocarcinoma
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
Background: PF-02341066 and PF-00299804 are drugs that specifically target certain proteins that may be more active in cancer cells than normal cells, in particular in non-small cell lung cancer.
- Conditions
- Carcinoma, Non-Small Cell Lung, Adenocarcinoma, Carcinoma, Squamous Cell, Carcinoma, Large Cell
- Trial name
- NCT01441128
- Testing
- PF-02341066/PF-00299804
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Gastrointestinal Tract
Study of GSK1363089 in Metastatic Gastric Cancer
This clinical study is being conducted at multiple sites to determine the best confirmed response rate, safety, and tolerability of GSK1363089 treatment in metastatic gastric carcinoma.
- Trial name
- NCT00725712
- Testing
- GSK1363089 (formerly XL880)
- Where
- 17 sites in United States
- Volunteers
- 74 people
- Sponsor
- GlaxoSmithKline